Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 561 clinical trials
None
Gemcitabine Nab-Paclitaxel and Bosentan for the Treatment of Unresectable Pancreatic Cancer

This phase I trial studies the side effects and best dose of bosentan and how well it works when given together with gemcitabine and nab-paclitaxel for the treatment of pancreatic cancer that cannot be removed by surgery (unresectable). Bosentan may block the hormone endothelin and prevent the growth and spread …

  • 0 views
  • 24 Nov, 2021
  • 1 location
None
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian Primary Peritoneal or Fallopian Tube Cancer

This phase II trial studies how well durvalumab and tremelimumab work in treating participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, …

cancer
serum pregnancy test
tumor cells
liver metastasis
x-rays
  • 112 views
  • 16 Oct, 2021
  • 2 locations
None
Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque

The aim of this prospective, open-label, randomized, single center study is to compare the effect of usual dose rosuvastatin plus ezetimibe and high-dose rosuvastatin on modifying atherosclerotic plaque.

rosuvastatin
ezetimibe
heart disease
intravascular ultrasound
stenosis
  • 10 views
  • 18 Nov, 2021
  • 1 location
None
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back after a period of improvement (relapsed) or has not responded to treatment (refractory). Immunotherapy with …

  • 43 views
  • 14 Nov, 2021
  • 3 locations
None
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, …

cancer
cutaneous lymphoma
monoclonal protein
serum pregnancy test
measurable disease
  • 60 views
  • 27 Feb, 2021
  • 4 locations
None
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has …

cancer
acalabrutinib
ibrutinib
monoclonal protein
chronic lymphocytic leukemia
  • 20 views
  • 08 Sep, 2021
  • 13 locations
None
Personalized CAPTEM Radiopeptide Therapy of Advanced Non-resectable Neuroendocrine Cancer

This is a non-randomized, phase II, open label study. The purpose of this study is to estimate Progression Free Survival (PFS) after treatment with Peptide Receptor Radionuclide Therapy (PRRT) 177Lu-DOTATOC standard dose (up to 4x7,4GBq 177Lu DOTATOC) in combination with capecitabine (CAP) and temozolomide (TEM) - CAPTEM. Patients with advanced, …

cancer
SPECT Scan
who 2017
progressive disease
radionuclide therapy
  • 5 views
  • 26 Jan, 2021
  • 1 location
None
A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification

This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Apatinib and Camrelizumab (Triplet-combined Therapy) for C-staged Hepatocellular Carcinoma in BCLC classification. The primary outcome measure is to evaluate the objective response rate (ORR) of Triplet-combined Therapy for C-staged Hepatocellular Carcinoma in BCLC …

  • 1 views
  • 22 May, 2021
  • 1 location
None
Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma

Phase I clinical trial on intra-tumoral ipilimumab plus intravenous nivolumab following the resection of recurrent glioblastoma. The aim of this clinical trial is to exploit the potential synergy of combined intra-tumoral CTLA-4 and systemic PD-1 blockade while minimizing the risk for increased immune-related toxicity by intratumoral administration of the CTLA-blocking …

temozolomide
neutrophil count
blood transfusion
recurrent glioblastoma
MRI
  • 134 views
  • 28 Jan, 2021
  • 1 location
None
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

This phase I/Ib trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV lung cancer. Alisertib may stop the growth of tumor cells by blocking a specific protein (Aurora Kinase A) that researchers believe may be important for …

cancer
EGFR
neutrophil count
lung cancer
ct scan
  • 0 views
  • 31 May, 2021
  • 1 location